ClinicalTrials.gg
Not yet recruitingNCT05750589COMFORTUpdated Apr 3, 2026

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

A Phase 3 interventional study of IRX-101 and Providone-Iodine in Retinal Disease, sponsored by iRenix Medical, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by iRenix Medical, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Retinal Diseases with a site in United States — 25 open to participants now, 41 under way, 5 of them phase 3. Retinal Diseases · United States.

Planned enrollment
20th of 111
240 · median 36
Started
2026
with 5 others
Phase 3
14 of 162
2 open now
Primary completion
2027-01
later than 14 of 37 live
Registered
138th of 162
by date

Among the 162 studies in Retinal Diseases with a site in United States, this one is the 20th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 14 of the 37 other live ones, and was the 138th registered.

Retinal Diseases

333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.

Browse Retinal Diseases studies →

Open to participants now

25 of the 162 studies in Retinal Diseases with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Retinal Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.

03

Conditions studied

  • Retinal Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes

Exclusion criteria

Exclusion Criteria:

  1. Current or past diagnosis of endophthalmitis
  2. Current diagnosis of uveitis
  3. Monocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eye
  4. Current use of viscous lidocaine products for ocular anesthesia prior to IVT
  5. Currently receiving intravitreal injections
  6. Concurrent participation in another clinical trial
  7. Females who are pregnant, planning to become pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    IRX-101

    Subjects randomized to IRX-101 will receive the investigational product, IRX-101.

    Drug: IRX-101

  • Active comparator
    5% Povidone-iodine

    Subjects randomized to this arm will receive the standard of care, Providone-iodine, at a concentration of 5%.

    Drug: Providone-Iodine

Interventions

  • IRX-101 is a novel ocular anti-septic

  • DrugProvidone-Iodine

    5% Providone-Iodine

06

What researchers measure

Primary outcomes

  1. Assessment of post-intravitreal injection eye pain

    Demonstrate the superiority of IRX-101 compared to PI in terms of reducing patient-reported post-intravitreal injection eye pain; pain will be assessed using the visual analog pain scale, a validated patient-reported outcome measure (questionnaire) for assessing patient's subjective pain and discomfort

    Time frame: Demonstrate a reduction in mean 1-hr post-injection pain scores

Secondary outcomes

  1. Change in post-IVT corneal epitheliopathy as evaluated by corneal fluorescein staining scores

    Demonstrate the superiority of IRX-101 compared to PI in terms of reducing corneal epitheliopathy / corneal fluorescein staining post-intravitreal injection; corneal staining will be obtained using validated Oxford Corneal Staining scale of 0 (no staining) to 5 (maximal corneal staining)

    Time frame: Immediately following intraviteral injection

07

Study locations

1 site
  • R. Gary Lane, II MD
    San Antonio, Texas 78240, United States
    • Francisco Angueira · Contact800-833-5921
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Mar 1, 2023
StartEst.
Sep 1, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05750589
Lead sponsor
iRenix Medical, Inc.
Responsible party
Sponsor
First posted
Mar 1, 2023
Start date
Sep 1, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 3, 2026

Study contacts

Stephen Smith, MD
Contact
stephen@irenix.com
650-785-1316
Stephen Smith, MD
study chair · Founder

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IRX-101

Start the discussion